Results 281 to 290 of about 314,420 (315)
Some of the next articles are maybe not open access.
Economics of chronic hepatitis B and hepatitis C
Journal of Hepatology, 2007Although not all patients develop progressive liver disease, chronic hepatitis B and chronic hepatitis C infections cause substantial morbidity and mortality worldwide. To address this need, many new antiviral treatments have become available over the past 10 years.
Arathi, Rajendra, John B, Wong
openaire +2 more sources
Pegylated interferons for chronic hepatitis B
Antiviral Research, 2003Conventional interferon therapy has been used for the treatment of chronic hepatitis B (CHB) for many decades. However, the use of interferon has been limited by its short half-life and high incidence of dose-related side effects. A meta-analysis investigating the short- and long-term consequences of interferon therapy showed that, whilst interferon ...
Craxi, A., Cooksley, W. G.
openaire +4 more sources
Coinfection of Chronic Hepatitis B and Fasciolosis
Infection, 2004Chronic hepatitis B and fasciolosis are associated with the induction of T-cell responses polarized to the Th2 subtype. Interferon-alpha enhances innate immunity as well as Th1 immune response. We present a male patient with chronic hepatitis B and fasciolosis who responded to chronic hepatitis treatment with hepatitis B virus (HBV) vaccine, interferon-
ISLER, M +4 more
openaire +4 more sources
JAMA, 2018
More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer.Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and ...
Lydia S Y, Tang +3 more
openaire +2 more sources
More than 240 million individuals worldwide are infected with chronic hepatitis B virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40% progress to cirrhosis, which may lead to liver failure and liver cancer.Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and ...
Lydia S Y, Tang +3 more
openaire +2 more sources
Lamivudine for chronic hepatitis B
Expert Review of Anti-infective Therapy, 2004Lamivudine (Epivir, GlaxoSmithKline) was approved by the US Food and Drug Administration for the treatment of adult patients with chronic hepatitis B in 1998, and has since been shown to be of benefit to selected patients with chronic hepatitis B. Drug resistance is the main issue encountered during therapy, with lamivudine resistant mutants emerging ...
openaire +2 more sources
Type B Hepatitis: Progression to Chronic Hepatitis
Clinics in Gastroenterology, 1980The ability to test for HBV associated antigens has provided evidence that viral hepatitis is a common cause of chronic liver disease world-wide. Fewer than 10% of cases of acute icteric HBV become chronic, but chronicity is more common after anicteric infections.
openaire +2 more sources
Intercurrent Hepatitis A in Chronic B Viral Hepatitis
JAMA: The Journal of the American Medical Association, 1982To the Editor.— Richard A. Willson, MD, reported a case of "Intercurrent Hepatitis A in B Viral Hepatitis" (1981;245:2495). The diagnosis of acute hepatitis A was made on the basis of first-generation type testing to distinguish between anti-HA-IgM and anti-HA-IgG. The "differential absorption" technique using staphylococcal cells has been reported to
openaire +2 more sources
Management of chronic hepatitis B
Journal of Hepatology, 2003Hari S, Conjeevaram, Anna Suk-Fong, Lok
openaire +2 more sources
Treatment of Chronic Hepatitis B and Chronic Hepatitis C
Reviews in Medical Virology, 1996openaire +2 more sources